Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination
Male
0301 basic medicine
[SDV]Life Sciences [q-bio]
Paul Gorochov
Antibodies, Viral
Cohort Studies
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Original Investigation
[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases
[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology
[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases
Desaint
Vaccination
Middle Aged
France Gorochov
[SDV] Life Sciences [q-bio]
[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology
[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
[SDV.IMM]Life Sciences [q-bio]/Immunology
Ninove
Female
France
2019-nCoV Vaccine mRNA-1273
Adult
COVID-19 Vaccines
[SDV.IMM] Life Sciences [q-bio]/Immunology
Paul
Villejuif
Ropers
Kieny
Lebbah
Rekacewicz
03 medical and health sciences
[SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology
Tartour
Durier
Humans
Hupé
Saliva
Immunity, Mucosal
BNT162 Vaccine
Aged
Vieillard
Lachatre); INSERM SC10-US019
SARS-CoV-2
COVID-19
Launay Desaint Vieillard Rekacewicz Lachatre); INSERM SC10-US019 Villejuif France Gorochov Ropers Launay Durier Desaint Vieillard Lachatre Parfait Hupé Ninove Kieny Tartour Paul Gorochov Ropers Lebbah Desaint Parfait Tartour Paul
Immunoglobulin A
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
Immunoglobulin G
[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
Lachatre
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Launay
[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
Parfait
DOI:
10.1001/jamanetworkopen.2024.8051
Publication Date:
2024-04-23T15:01:59Z
AUTHORS (35)
ABSTRACT
Importance There is still considerable controversy in the literature regarding capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response. Objective To compare serum and salivary IgG IgA levels among mRNA-vaccinated individuals with or without previous SARS-CoV-2 infection. Design, Setting, Participants In this cohort study, SARS-CoV-2–naive participants those infection were consecutively included CoviCompare P M mRNA trials followed up day 180 after either BNT162b2 (Pfizer-BioNTech) vaccine mRNA-1273 (Moderna) at beginning COVID-19 campaign (from February 19 June 8, 2021) France. Data analyzed from October 25, 2022, July 13, 2023. Main Outcomes Measures An ultrasensitive digital enzyme-linked immunosorbent assay was used for comparison spike-specific levels. Spike-specific secretory level also quantified selected times. Results A total 427 3 groups: prior who received 1 single dose (n = 120) 2 doses 172) 135). The median age 68 (IQR, 39-75) years, 228 (53.4%) men. saliva increased injections individuals. After vaccination, SARS-CoV-2–specific levels, normalized respect significantly higher infection, as compared most responsive recipients (median 155 × 10 −5 vs 37 29; 107 54 57; 104 70 [ < .001]). contrast, 1, BNT162b2-vaccinated group only 57 (36 49 .01]). Bona fide multimeric antigenic stimulations optical density, 0.36 [IQR, 0.16-0.63] 0.16 0.10-0.22]; .001). Conclusions Relevance findings study suggest that associated immunity but much lower than previously infected Further studies are needed determine association between specific prevention transmission.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (18)
CITATIONS (15)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....